BIOCORP Signs Distribution Agreement for Mallya Technology With Roche Diabetes Care France
30.6.2020 08:30:00 EEST | Business Wire | Press release
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME), a French company specialized in the development and manufacturing of medical devices and smart drug delivery systems, announces today the signature of a distribution contract for its Mallya connected device with Roche Diabetes Care France.
As part of the agreement, Roche Diabetes Care France will distribute Mallya to pharmacies in France. This medical device is an intelligent 2-year reusable injector pen sensor that is compatible with the majority of insulin injection pens, both disposable and reusable. It automatically collects the insulin dose delivered with near 100% accuracy.
In the future, Mallya will also be part of the RocheDiabetes ecosystem consisting of connected blood glucose meters (Accu-Chek Mobile, Accu-Chek Guide) and digital solutions for better patients care.
Gluci-Chek is a smartphone application regularly used by nearly 60,000 diabetic patients in France. It brings together three major functionalities for personalized diabetes management: a carbohydrate calculation tool with visualization of portions on the plate, a self-monitoring glycemic logbook and a graphic visualization of glycemic results.
Thanks to Mallya, the patient will no longer have to manually report the insulin doses injected in the future since, once the sensor is paired with the Gluci-Chek application, the data will be automatically reported and displayed in the blood glucose monitoring logbook, regardless of the insulin pen1.
Frédéric Jacquey, President of Roche Diabetes Care France: “The signature of this agreement with Biocorp represents a fundamental step in the development of our ecosystem to improve the care of diabetic patients and their exchanges with healthcare professionals. With innovative technology like Mallya, we will soon be able to offer a unique offering for optimal patient care that integrates blood glucose data from our meters via Gluci-Chek and automatic insulin data via Mallya.”
Éric Dessertenne, CEO of BIOCORP: “Roche is the second pharmaceutical giant to integrate our Mallya connected device for optimal monitoring of diabetic patients into its commercial offer. I would like to thank the teams at Roche Diabetes Care France for their responsiveness over the last few weeks. This new structuring agreement confirms the ambitions presented to all our shareholders in early 2020 on the market of digitalization of diabetes and the considerable commercial potential of Mallya. With a partner of the calibre of Roche, we are confident that a large number of diabetics will quickly be able to benefit from the real benefits offered by Mallya on the secure monitoring of their daily insulin intake."
ABOUT DE ROCHE DIABETES CARE FRANCE
Roche Diabetes Care is a healthcare company specializing in diabetes. For more than 40 years, it has been designing solutions to meet the needs of both patients and healthcare professionals: medical devices (blood glucose meters, lancing devices, insulin pumps), services (information and therapeutic education support) and digital solutions (applications, platform for sharing blood glucose data between patients and healthcare professionals). By creating an ecosystem connecting medical devices and digital solutions, Roche Diabetes Care is paving the way for personalized diabetes management with the aim of facilitating and optimizing the management and monitoring of this complex disease.
Roche Diabetes Care France is a subsidiary of the Roche Group in France, alongside Roche SAS France and Roche Diagnostics France. For more information, please visit www.roche.fr.
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This intelligent sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of diabetics. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 54 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com.
Follow us on Twitter @BIOCORPSystems
1 SoloStar de Sanofi – KwikPen de Eli Lilly – FlexPen de Novo Nordisk
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200629005362/en/
Contact information
BIOCORP CONTACTS
Sylvaine Dessard
rp@biocorp.fr
+ 33 (0)6 88 69 72 85
Bruno ARABIAN
barabian@ulysse-communication.com
+33 (0)6 87 88 46 26
ROCHE DIABETES CARE FRANCE CONTACTS
Myriam Hamza
rochediabpresse@havas.com
+33 (0)6 45 87 46 51
Raphaële Badel
Raphaele.badel@roche.com
+33 (0)7 77 34 60 59
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Unveils a Global Framework to Protect Critical Organisations from Frontier AI Attacks1.10.2026 14:18:00 EEST | Press release
At the Thales Cyber Summit held in Paris (France) , Thales today unveiled a global response to the challenges created by Frontier AI models. Reasoning, autonomy and scale of these cutting-edge systems far exceed previous generations, and can accelerate vulnerability discovery, exploit development and cyberattack execution at machine speed. This marks a shift in AI from a tool that assists humans to one that acts autonomously, reshaping the threat landscape for organisations, the first of which those operating critical systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001459724/en/ ©Thales “Frontier AI models represent a new inflection point for cybersecurity. The challenge is not only technological; it is about helping organisations act before risks materialize, understand the implications, assess their exposure, and, if an attack still succeeds, ensure resilience and quick recovery. By combining advanced technologi
MidOcean Concludes 2026 Equity Raise, Securing More Than $4 Billion of Equity Commitments to Accelerate Global LNG Growth Strategy1.10.2026 14:00:00 EEST | Press release
MidOcean Energy ("MidOcean" or the "Company"), a liquefied natural gas (LNG) company formed and managed by EIG, today announced the conclusion of its 2026 equity capital raise, securing more than $4 billion of closed and pending commitments over the last 12 months from new strategic and institutional investors, as well as significant re-ups from existing investors. The capital committed significantly exceeded the Company's original target of $2 billion, reflecting continued confidence in MidOcean's strategy, portfolio, team and long-term growth outlook. The raise includes commitments from strategic investors, sovereign-linked institutions and financial investors. Among the new investors are the Private Department of Sheikh Mohammed bin Khalid Al Nahyan, Idemitsu Kosan, NYK Line (through Diamond Gas MidOcean), The Arab Energy Fund, Shizuoka Gas and certain Korean institutional investors. The proceeds are expected to enhance MidOcean's balance sheet flexibility and position the Company t
LISTERINE ® Launches Oral Care Counts This World Smile Day as Oral Disease Cases Rise to 3.73 Billion1.10.2026 13:45:00 EEST | Press release
Nearly half the world’s population is affected by oral disease – and the number of cases is rising. This World Smile Day, LISTERINE® is launching Oral Care Counts – a multiyear education and advocacy initiative showing why oral health is an essential part of overall health and how practical daily habits, including a three-step oral care routine of brushing, flossing and rinsing, can support better oral health.The multiyear education and advocacy campaign is designed to help more people understand the essential role oral health plays in overall health and wellbeing, and how realistic daily habits can make prevention more achievable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001163338/en/ Oral Care Counts aims to bring together healthcare professionals, advocates, policymakers, community organizations, and consumers to raise understanding of oral health as an essential part of overall health and wellbeing. The initiati
Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates1.10.2026 11:30:00 EEST | Press release
Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the companies have entered into a global license, development, and commercialization agreement for up to six potential biosimilar candidates, with two confirmed investigational biosimilar candidates, SB41, a biosimilar candidate referencing Fasenra®1 (benralizumab), and SB44, a biosimilar candidate referencing Ilaris®2 (canakinumab). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001835078/en/ Under the terms of the agreement, Samsung Bioepis will be responsible for the development, regulatory registration, and manufacture of the biosimilars, while Teva will be responsible for commercialization in global markets, including the United States (U.S.), Europe, and Canada. The companies have agreed to an option for expanding the partnership to other territories. This agreement reinforces the long-standing and successful
FPT and ZEBOX Partner to Advance AI and Sustainable Innovation in Logistics1.10.2026 11:00:00 EEST | Press release
FPT, a global technology and IT services provider, and ZEBOX, the international innovation accelerator initiated by the CMA CGM Group, have entered into a three-year strategic partnership to develop and deploy AI-powered solutions for the transport and logistics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001622214/en/ The partnership was formalized during the Vietnam - France Leaders Forum, held as part of Vietnam’s General Secretary and State President’s official visit to France. The partnership will combine FPT’s expertise in artificial intelligence, automation and large-scale digital transformation with ZEBOX’s innovation network and its close connection to the CMA CGM Group’s global transport and logistics ecosystem. The partners will focus on shipping, port operations, logistics, supply chain management and clean energy. A first joint initiative in Vietnam As a first step, FPT, ZEBOX and CMA CGM Vietnam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom